Avanir Pharmaceuticals, Inc. (AVNR) reported a second-quarter net loss of $17.0 million or $0.13 per share, wider than the net loss of $14.5 million or $0.12 per share in the same period last year.
On average, 6 analysts polled by Thomson Reuters expected the company to report a loss of $0.12 per share for the quarter. Analysts' estimates typically exclude special items.
Total revenues for the quarter rose to $10.0 million from $1.4 million a year ago. These revenues consists of NUEDEXTA revenue and royalty revenue from Abreva.
Analysts expected revenues of $7.81 million for the quarter.
NUEDEXTA is a FDA-approved treatment for pseudobulbar affect, which can be caused by a variety of neurological diseases and brain injury.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.